Renovaro Inc
RENB
查看详细走势图
1.420USD
0.000
收盘 12/22, 16:00（美东）报价延迟15分钟
251.90M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
0.00%
5天
0.00%
1月
0.00%
6月
+315.93%
今年开始到现在
+69.96%
1年
-13.41%
查看详细走势图
TradingKey Renovaro Inc股票评分
单位: USD 更新时间: 2025-09-30操作建议
Renovaro Inc当前公司基本面数据相对谨慎，当前估值合理，机构持股占比非常高，近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Renovaro Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Renovaro Inc亮点
亮点风险
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
估值低估
公司最新PE估值-5.82，处于3年历史低位
机构加仓
最新机构持股65.41M股，环比增加6.49%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值4.92M
活跃度降低
近期活跃度降低，过去20天平均换手率-0.33
Renovaro Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Renovaro Inc简介
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
公司代码RENB
公司Renovaro Inc
CEOWeinstein (David)
网址
常见问题
Renovaro Inc(RENB)的当前股价是多少？
Renovaro Inc(RENB)的当前股价是 1.420。
Renovaro Inc的股票代码是什么？
Renovaro Inc的股票代码是RENB。
Renovaro Inc股票的52周最高点是多少？
Renovaro Inc股票的52周最高点是21.000。
Renovaro Inc股票的52周最低点是多少？
Renovaro Inc股票的52周最低点是1.130。
Renovaro Inc的市值是多少？
Renovaro Inc的市值是251.90M。
Renovaro Inc的净利润是多少？
Renovaro Inc的净利润为-178.01M。
现在Renovaro Inc(RENB)的股票是买入、持有还是卖出？
根据分析师评级，Renovaro Inc(RENB)的总体评级为--，目标价格为--。
Renovaro Inc(RENB)股票的每股收益（EPS TTM）是多少
Renovaro Inc(RENB)股票的每股收益（EPS TTM）是-0.244。
相关品种
